Uptake of tumour necrosis factor – alpha inhibitor biosimilars for psoriasis: A drug utilisation study from BADBIR
BJD, 2023.
Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CEM, Lunt M, Warren RB, Yiu ZZN; BADBIR Study Group.
Read publication: BJD
Related
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Sec...
Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prosp...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective c...
0 Comments